
Neuphoria Therapeutics Inc. (NEUP)
Last updated: 2026-10-28 08:56:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Neuphoria Therapeutics Inc. (NEUP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.41, with a market capitalization of $18.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.19 to $5.53. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$18.29M | |
$3.40 | |
$21.40 | |
$2.90 | |
$3.38 | |
3.16K | |
31.28K | |
-- | |
$5.53 | |
$3.19 | |
-- | |
-- |
Neuphoria Therapeutics Inc. (NEUP) Pre-Market Stock Price
Neuphoria Therapeutics Inc. (NEUP) is trading at $3.40 in pre-market trading as of 2026-10-27 23:31:00, up 0.44% ($0.02) from the previous close of $3.38
Pre-market trading shows how investors are pricing NEUP before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Neuphoria Therapeutics Inc. (NEUP) 7-Day Stock Price Change
Over the past seven days, Neuphoria Therapeutics Inc. (NEUP) moved from $3.31 to $3.41, representing a gain of 2.99% ($0.10).
The stock traded between $3.24 and $3.59 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 25.32 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
NEUP 52-Week Price Position
Position in Range: 9.4%
NEUP is currently trading at $3.41, placing it 9.4% of the way from its 52-week low of $3.19 to its 52-week high of $5.53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Neuphoria Therapeutics Inc. (NEUP)?
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Neuphoria Therapeutics Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Neuphoria Therapeutics Inc. (NEUP) Stock on MEXC
Eligible investors can buy real shares of Neuphoria Therapeutics Inc. (NEUP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Neuphoria Therapeutics Inc. (NEUP) stock price today?
2.Is NEUP stock going up or down today?
3.What is NEUP pre-market price?
4.What is NEUP after-hours price?
5.Is NEUP stock trading now?
6.Where does NEUP sit relative to its 52-week high and low?
7.What sector is Neuphoria Therapeutics Inc. in?
8.What is Neuphoria Therapeutics Inc.'s market capitalization and where is it listed?
9.How is NEUP valued in terms of P/E ratio and EPS?
10.Does Neuphoria Therapeutics Inc. pay a dividend?
Explore More US Stocks
Search Stocks
NEUP Stock Calculator
Estimate the value between NEUP shares and USD.
NEUP Shares to USD
1.00 NEUP shares = 3.409 USD
Calculations are estimates based on the latest available price and are for reference only.

